文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

接受挥发性麻醉药治疗的濒死性哮喘患者的特征与结局:一项回顾性观察性队列研究

Characteristics and Outcomes of Patients Receiving Volatile Anesthetics in Near-Fatal Asthma: A Retrospective Observational Cohort Study.
PubMed 文献 · Crit Care Explor · 2025-07-30
一句话结论在濒死性哮喘机械通气患者中,吸入挥发性麻醉药似乎可行且安全,但无法直接推断疗效。

这项单中心回顾性观察性队列研究纳入2016年1月至2023年8月因濒死性哮喘接受机械通气≥24小时和/或ECMO的成人患者62例,其中38例(61.3%)接受挥发性麻醉药治疗。挥发性麻醉药组治疗前通气和血气参数更差、气压伤更多、更常接受ECMO;尽管如此,该组潮气量平均增加204 mL(83.9%;95%CI 110-298;p<0.001)。挥发性麻醉药组与无挥发性麻醉药组的中位机械通气时间分别为10天(8-16天)vs 5天(3-10天;p=0.001),ICU住院时间分别为15天(13-20天)vs 9天(7-14天;p=0.001),ICU死亡率分别为5.3% vs 4.2%,90天死亡率分别为5.3% vs 4.2%。作者认为,吸入挥发性麻醉药(包括ECMO期间)似乎可行且安全,临床结局良好,但无法直接推断疗效。

要点

  • 在62例濒死性哮喘机械通气成人中,38例(61.3%)使用挥发性麻醉药,32例(51.6%)需要ECMO。
  • 挥发性麻醉药组治疗前通气和血气参数更差、气压伤更多、更常接受ECMO,但潮气量平均增加204 mL(83.9%;95%CI 110-298;p<0.001)。
  • 挥发性麻醉药组与无挥发性麻醉药组中位机械通气时间分别为10天(8-16天)vs 5天(3-10天;p=0.001),ICU住院时间分别为15天(13-20天)vs 9天(7-14天;p=0.001)。
  • 挥发性麻醉药组与无挥发性麻醉药组ICU死亡率分别为5.3% vs 4.2%,90天死亡率分别为5.3% vs 4.2%。
  • 作者认为吸入挥发性麻醉药(包括ECMO期间)似乎可行且安全且临床结局良好,但无法直接推断疗效。

适用人群与场景

  • 年龄≥16岁、因濒死性哮喘接受机械通气≥24小时和/或ECMO的成人患者,收治于三级重症监护与ECMO单元,时间范围为2016年1月至2023年8月。

研究设计与关键结果

  • 研究类型为回顾性单中心观察性队列研究,纳入62例患者(62.9%为女性),中位(IQR)年龄45岁(29-51岁)。
  • 基线中位(IQR)pH 7.13(6.93-7.23),Paco2 12.9 kPa(8.7-16.2 kPa),潮气量178 mL(50-300 mL)。
  • 大多数患者接受静脉支气管扩张剂,32例(51.6%)需要ECMO,38例(61.3%)接受挥发性麻醉药治疗。
  • 挥发性麻醉药组治疗前通气和血气参数更差、气压伤更多、更可能接受ECMO。
  • 挥发性麻醉药组潮气量平均增加204 mL(83.9%;95%CI 110-298;p<0.001)。
  • 挥发性麻醉药组与无挥发性麻醉药组中位机械通气时间分别为10天(8-16天)vs 5天(3-10天;p=0.001),ICU住院时间分别为15天(13-20天)vs 9天(7-14天;p=0.001)。
  • 挥发性麻醉药组与无挥发性麻醉药组ICU死亡率分别为5.3% vs 4.2%,90天死亡率分别为5.3% vs 4.2%。

证据类型、等级与局限

  • 证据类型:回顾性单中心观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在濒死性哮喘中吸入挥发性麻醉药(包括ECMO期间)似乎可行且安全,临床结局良好,但无法直接推断疗效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE AND OBJECTIVES: Inhaled volatile anesthetics are employed as rescue therapy in near-fatal asthma, despite limited evidence. This study aims to describe the characteristics, management, and outcomes of mechanically ventilated adult patients with near-fatal asthma, stratified by the use of volatile anesthetic therapy.

DESIGN: Retrospective single-center observational cohort study.

SETTING: Tertiary critical care and extracorporeal membrane oxygenation (ECMO) unit.

PARTICIPANTS: Adults 16 years old or older receiving mechanical ventilation (MV) for greater than or equal to 24 hours and/or ECMO between January 2016 and August 2023 for near-fatal asthma.

MAIN OUTCOMES AND MEASURES: We recorded demographics, disease severity tidal volumes, and ventilator settings, by treatment over the first 100 hours. Outcomes were duration of ECMO and MV, ICU length of stay, 90-day mortality, and adverse drug reaction.

RESULTS: Sixty-two patients were included (62.9% female), with a median (interquartile range [IQR]) age of 45 years (29-51 yr). Median (IQR) pH 7.13 (6.93-7.23), Paco2 12.9 kPa (8.7-16.2 kPa), and tidal volume 178 mL (50-300 mL). Most patients received IV bronchodilators and 32 (51.6%) required ECMO. Thirty-eight patients (61.3%) were treated with volatile anesthetics. Volatile patients had worse ventilation and blood gas parameters before treatment, more barotrauma, and were more likely to be receiving ECMO. Despite this, improvements in tidal volume occurred in the volatile group (mean increase, 204 mL [83.9%]; 95% CI, 110-298; p < 0.001). Median (IQR) duration of MV and ICU length of stay in volatile and no volatile patients were 10 days (8-16 d) vs. 5 days (3-10 d; p = 0.001) and 15 days (13-20 d) vs. 9 days (7-14 d; p = 0.001), respectively. ICU and 90-day mortality in volatile and no volatile patients were 5.3% vs. 4.2%.

CONCLUSIONS AND RELEVANCE: The use of inhaled volatile anesthetics for near-fatal asthma, including during ECMO, appears to be feasible and safe, and with favorable clinical outcomes; however, no conclusions regarding efficacy can be directly inferred.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Remmington C, Camporota L, Taylor D, et al. Characteristics and Outcomes of Patients Receiving Volatile Anesthetics in Near-Fatal Asthma: A Retrospective Observational Cohort Study. Crit Care Explor. 2025. PMID: 40737011. doi:10.1097/CCE.0000000000001295

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。